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Supplemental methods
Baseline characteristics
BMI was calculated as weight divided by height squared (kg/m 2 ). Diabetes mellitus was defined as a fasting serum glucose concentration of ≥7.0 mmol/L or a non-fasting serum glucose concentration of ≥11.1 mmol/L or the use of blood glucose-lowering medications [1] . Hypertension was defined as a resting blood pressure above 140/90 mmHg or the use of blood pressure-lowering medication. The diagnosis of heart failure was based on follow-up using the medical records of the participants [2] .
Coronary Heart Diseases (CHD) was defined as a compound outcome including fatal or nonfatal myocardial infarction or CHD mortality [2] .
Systematic review
We conducted an extensive electronic literature search of Embase, Medline Ovid, and
Cochrane Central using multiple search terms ( Supplementary Table S1 ) to identify all articles investigating ADRB2 polymorphisms; rs1042713 and/or rs1042714 and/or their haplotypes and COPD exacerbations in patients exposed to β 2 -agonists. Our literature search was restricted to studies published in English from inception until 30 September 2019.
Additional potentially relevant articles were searched through article reference lists.
Review criteria and data extraction
We considered all original articles, excluding conference abstracts, editorials, short surveys, and animal studies. We did not set any limits on study design, sample size, location, or follow-up. Studies were included if they met the following three criteria;
(1) COPD patients exposed to inhaled short-acting β 2 -agonists (SABA) and/or long-acting β 2agonists (LABA) were eligible to be included in the review.
(2) The exposure variable of interest was ADRB2 polymorphisms; rs1042713 and/or rs1042714 and/or their haplotypes. The first author (LK) screened all studies from their titles and abstracts and excluded those that were not relevant. The full texts of potential papers were assessed independently by two authors (LK and KV). In case of heterogeneity across studies, the results of each study were reported individually.
Supplemental results
The literature search yielded 369 hits, of which 270 unique articles remained after excluding duplicates. Of these 270 articles, the title and abstract were reviewed and 236 articles were excluded (conference abstracts (26), editorials (10), experimental studies (5), short surveys (5) and as they were unrelated to the association between ADRB2 polymorphisms and treatment response to inhaled β 2 -agonist in patient with COPD (190). We reviewed 34 fulltext articles and 27 of these were excluded for the following reasons; review article (13), letter (1), focus on other SNPs in ADRB2 (3), focus on different outcomes (10). In total, three clinical trials and four observational studies were withheld, but in the latter, not all of the included patients were on treatment with inhaled β 2 -agonist ( Figure S2 ).
Briefly, the three clinical trials that met inclusion criteria [3] [4] [5] were published between 2012 and 2014. The sample size ranged from 565 to 2,561. Two studies were multicentre, and another one was from the United States. One assessed the association between the SNPs and time to first COPD exacerbation using Kaplan-Meier curves and the log-rank test. Gly16Gly (p=0·0018) and Arg16Gly (p=0·0130) genotypes [4] . They found no significant differences in exacerbation risk between the genotypes of rs1042714. [4] Two other studies [3, 5] assessed the association of the SNP(s) with the number of COPD exacerbations. One of them used Poisson regression to asses this association and while the other study described the distribution of the number of COPD exacerbation across the genotype categories of rs104213.
They found no significant association between the SNPs and COPD exacerbations in COPD patients using LABA [3, 5] .
In our search, four observational studies [6] [7] [8] [9] also evaluated the association of the SNP(s) with the number of COPD exacerbations. They were published between 2009 and 2019 and included patients from hospitals, medical centres, outpatient clinics, and the general population. Their sample size ranged from 61 to 5,219. However, not all of the included patients in these four observational studies were on treatment with inhaled β 2 -agonist. The results of a recent observational study showed an increased risk of COPD exacerbations in carriers of Arg16 and Gln27 [9] . However, the proportion of COPD patients treated with LABA from the Copenhagen General Population Study was low (9.8 %) [9] . Due to differences in assessments and definitions of the outcome, this precluded a meta-analysis 6 with pooling of results. Therefore, we reported the findings separately for each study in Table   5 in the main text. .ab,ti.))) AND (Pulmonary Disease, Chronic Obstructive/ OR (copd OR (chronic* ADJ3 obstruct* ADJ3 (lung OR pulmonar*))).ab,ti.) AND english.la.
Cochrane CENTRAL
((adrb2 OR adrb-2):ab,ti OR (((((beta OR β OR beta2 OR β2) NEAR/3 adrenerg* NEAR/3 receptor*) OR ((beta OR β OR beta2 OR β2) NEAR/3 (adrenorecept* OR adrenocept* OR agonist*))):ab,ti) AND ((haplotype* OR polymorph* OR genetic* OR pharmacogenetic* OR snp OR genom* OR gwas):ab,ti))) AND ((copd OR (chronic* NEAR/3 obstruct* NEAR/3 (lung OR pulmonar*))):ab,ti) 
